Posted by Michael Wonder on 17 Aug 2018
FDA approves Eylea (aflibercept) injection sBLA in wet age-related macular degeneration
17 August 2018 - Regeneron Pharmaceuticals today announced that the U.S. FDA has approved a supplemental biologics license application for Eylea (aflibercept) Injection in patients with wet age-related macular degeneration.
The application was based on second-year data from the Phase 3 VIEW 1 and 2 trials in which patients with wet age-related macular degeneration were treated with a modified 12-week dosing schedule (doses given at least every 12 weeks, and additional doses as needed). These data are now included in the updated Eylea label.
